Patents by Inventor Tilman Schneider-Hohendorf

Tilman Schneider-Hohendorf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION TREATMENT FOR MULTIPLE SCLEROSIS
    Publication number: 20170002077
    Abstract: The present application provides evidence that a combined blockade against alpha-4 integrin and MCAM is more effective than against either molecule alone. In consequence, the invention provides methods of combination treatment in which both an antagonist of alpha-4 integrin and an MCAM antagonist are administered to a subject having or at risk of multiple sclerosis or other autoimmune disease.
    Type: Application
    Filed: March 12, 2015
    Publication date: January 5, 2017
    Inventors: Stephen Jed Tam, Theodore Yednock, Yue Liu, Nicholas Schwab, Heinz Wiendl, Tilman Schneider-Hohendorf
  • METHODS OR RISK ASSESSMENT OF PML AND RELATED APPARATUS
    Publication number: 20150105278
    Abstract: The invention provides a method of assessing the risk of occurrence of progressive multifocal leukoencephalopathy (PML) in a subject as well as a method of stratifying a subject undergoing VLA-4 blocking agent treatment for suspension of VLA-4 blocking agent treatment. These methods comprise detecting the level of L-selectin (CD62L) and optionally LFA-1 expressing T cells in a sample from the subject.
    Type: Application
    Filed: October 16, 2012
    Publication date: April 16, 2015
    Applicant: WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
    Inventors: Nicholas Schwab, Tilman Schneider-Hohendorf, Heinz Wiendl
  • ASSESSMENT OF PML RISK AND METHODS BASED THEREON
    Publication number: 20140315188
    Abstract: The invention provides a method of assessing the risk of occurrence of progressive multifocal leukoencephalopathy (PML) in a subject as well as a method of stratifying a subject undergoing ?4-integrin and/or VLA-4 blocking agent treatment for suspension of the treatment and a method of stratifying a subject undergoing Highly Active Antiretroviral Therapy (HAART) for alteration of HAART. These methods comprise detecting the level of P-selectin glycoprotein ligand-1 (PSGL-1) expressing T cells in a sample from the subject.
    Type: Application
    Filed: October 16, 2012
    Publication date: October 23, 2014
    Inventors: Nicholas Schwab, Tilman Schneider-Hohendorf, Heinz Wiendl